XL647 is a novel spectrum-selective kinase inhibitor for EGFR, ErbB2, KDR, Flt-4 and EphB4 with IC50 of 0.3 nM, 16 nM, 1.5 nM, 8.7 nM and 1.4 nM, respectively.

>98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

EXEL-7647,xl-647,xl 647

Powder

DMSO : ≥ 30 mg/mL (61.05 mM)

Ephrin Receptor

XL-647 potently inhibits the EGF/ErbB2, VEGF, and ephrin RTK families. XL-647 is a reversible and ATP competitive inhibitor. XL-647 was inactive against a panel of 10 tyrosine kinases (including the insulin and the insulin-like growth factor-1 receptor) and 55 serine-threonine kinases (including cyclin-dependent kinases, stress-activated protein kinases, and protein kinase C isoforms). XL-647 inhibits cellular proliferation and EGFR pathway activation in the erlotinib-resistant H1975 cell line that harbors a double mutation (L858R and T790M) in the EGFR gene. In A431 cells, XL-647 reduces cell viability with IC50 values of 13 nM.

XL-647 shows potent and long-lived inhibition of the WT EGFR in vivo. XL-647 substantially inhibits the growth of H1975 xenograft tumors and reduces both tumor EGFR signaling and tumor vessel density.